MolMed acute leukaemias: Contribution of TK presented at the BMT Tandem Meetings

MolMed S.p.A. announces the results of the contribution given by its investigational cell-based therapy TK to the treatment of haematologic malignancies through bone marrow transplantation from partially matched donors, presented at the Blood & Marrow Transplantation Tandem Meetings, the combined annual meeting of the Center for International Blood ... (more)

http://www.groundreport.com/Health_and_Science/MolMed-acute-leukaemias-Contribution-of-TK-present/2951404